Michael Cullen, DPM
Podiatrist · Omaha, NENPI 1851329114
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (43.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Arthrex at 39.2% of the total. Reporting peaked in 2021 at $5,088 and has fallen 87.0% since, to $659 in 2025.
Across 78 payments — averaging $105.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrex$3K
- Stryker$2K
- Conetic Solutions, Inc.$2K
- Avinger Inc.$118
- Johnson & Johnson$70
- Polynovo North America LLC$46
- plus $96 from 5 others
What the payments were for
- Travel & lodging$1,16414%
- Food & beverage$3,36241%
- Education$3,60044%
- Gifts$941%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrex | 16 | $3,226 |
| Stryker(2 entities) | 40 | $2,473 |
| Conetic Solutions, Inc. | 12 | $2,191 |
| Avinger Inc. | 1 | $118 |
| Johnson & Johnson | 2 | $70 |
| Polynovo North America LLC | 2 | $46 |
| RSW Medical Company, Inc. | 1 | $32 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $18 |
| Ossio Inc | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Nevro Corp. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ANCHORAGE$447
- ORTHOLOC 2 LAPIFUSE$283
- AUGMENT INJECTABLE$170
- PROPHECY$170
- 7 X 23MM CITRELOCK IMPLANT$170
- SALVATION$119
- PANTHERIS$118
How this compares
$8,221 in reported general payments places this provider in the 85th percentile of 29 podiatrist providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nitroglycerin PatchNitroglycerin | 17 | $883 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 16 | $289 |
| Ondansetron OdtOndansetron | 15 | $71 |
Paid to pharmacies, not to this prescriber.
Other podiatrist in Omaha
- Nathan PenneyOmaha$16K
- Glenn YorkOmaha$10K
- Emlyn ForsungOmaha$9K
- Chad SummyOmaha$4K
- Elizabeth KlawitterOmaha$3K
- Steven MeinholdOmaha$3K
- Michael PowersOmaha$138
- David CornellOmaha$23
- Donald BuddeckeBellevue$47K
- Scott ShindlerWausa$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.